Strong year-to-date (24.59%) and one-year (23.24%) returns, competitive expense ratio of 0.37%, Zacks ETF Rank of 2 (Buy), substantial assets under management ($1.46 billion), and effective diversification with 63 holdings make it an attractive investment option.
The ETF has demonstrated strong performance with a 49.25% surge from 52-week low, recently hit 52-week high, holds a Zacks Rank #2 (Buy) rating, and shows positive weighted alpha of 27.41, indicating potential for continued gains. The underlying healthcare sector benefits from improving earnings, clinical developments, and defensive appeal.
Articles that tag IHF but are mainly about other companies.
Democratic lawmakers expected to restore enhanced ACA subsidies and reverse Medicaid cuts, improving enrollment prospects and reducing reimbursement uncertainty for healthcare providers.
Expected to benefit from favorable healthcare policy changes and increased support for healthcare providers.
Up 24.7% year-to-date, gaining from healthcare sector's improved fundamentals and defensive appeal.
Lower drug prices reduce insurers' pharmacy costs, potentially improving medical-loss ratios. Mixed-to-moderately positive impact expected as healthcare providers benefit from cost savings.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology